Work

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation

Year: 2015

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdv066

Authors: S. Fu, M.M. Hou, A. Naing, F. Janku, K. Hess, R. Zinner, V. Subbiah, D. Hong, J. Wheler, S. Piha-Paul, A. Tsimberidou, D. Karp, D. Araujo, B. Kee, P. Hwu, R. Wolff, R. Kurzrock, F. Meric-Bernstam

Institutions: Chang Gung University, Chang Gung Memorial Hospital, Taoyuan Chang Gung Memorial Hospital, Linkou Chang Gung Memorial Hospital, The University of Texas MD Anderson Cancer Center, University of California San Diego, Moores Cancer Center

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, University of Texas MD Anderson Cancer Center, National Cancer Institute

Awards: G111615301, Cancer Center Support Grant

OpenAlex ID: W2117430947

FWCI: 3.086

Cites: 31

Cited by: 70

Related to: 10